Danaher's Q2: The Bioprocessing Timing Mirage and a Life Sciences Inflection
Core growth accelerates, but resin pushouts mask robust order trends; Masimo lifts guidance.
DHR · Earnings Call · 2026-07-21
Bioprocessing: A Timing Mirage or a Warning?
Danaher's second quarter was a study in contrasts. The headline numbers—3% core growth, a 150 bp acceleration from Q1—came in ahead of expectations, and management raised full-year EPS guidance on the back of the earlier-than-expected close of Masimo. But the market's focus quickly turned to bioprocessing, where revenue growth decelerated to low single digits and the full-year outlook was trimmed from high single digits to mid-single digits. The culprit? A handful of large chromatography resin shipments pushed from 2026 into 2027—roughly $100 million of revenue. As CFO Matt Gugino explained, "that's a couple of hundred basis points to our bioprocessing growth for the full year."
While revenue was impacted by customer timing, underlying demand remained very healthy, with mid-teens order growth in both consumables and equipment.
The pushouts are concentrated among a few large commercial customers, not a broad-based demand signal. Management emphasized that the molecule pipeline and commercial drug production remain robust, and funnel activity continues to build. In fact, orders grew mid-teens in both consumables and equipment—a level that historically has been a reliable leading indicator. This is not the inventory glut of 2023; lead times have shortened and safety stocks are lean. As Rainer Blair put it, "we think it's highly unlikely that it does not return in 2027."
The market may be overreacting to the headline cut. The company's long-term confidence in high single-digit growth for bioprocessing is intact, and the pushouts are a timing issue, not a demand issue. For investors, this could be an opportunity to focus on the order book rather than the quarterly revenue miss.
Life Sciences Finds Its Footing
The standout of the quarter was Life Sciences, which delivered 5.5% core growth—the strongest in years. The recovery is broad-based: biopharma customers are investing again, biotech funding is translating into orders, and even academic market showed nascent signs of stabilization. "We were particularly pleased to see an acceleration in core growth versus the first quarter, driven by good commercial execution, recent innovation, and recovery in our end markets," said Rainer.
Pall's applied filtration jumped ~10%, led by microelectronics, while SCIEX and Beckman Life Sciences posted solid gains. Abcam delivered its best quarter since acquisition, helped by commercial initiatives in pharma and diagnostics. The company raised its full-year Life Sciences growth outlook, reflecting a faster recovery than initially assumed, and the Beckman Life Science automation franchise is riding the wave of AI-enabled autonomous labs.
This is a meaningful inflection after two years of flat-to-down results. The revenue trajectory is improving, and the segment now has momentum heading into the back half.
Masimo, Diagnostics, and the Capital Flywheel
Diagnostics grew 2% core, but excluding respiratory, 5%—and China's VBP headwinds are moderating. New blood-based Alzheimer's assays at Beckman and continued menu expansion at Cepheid are underappreciated growth drivers. "In China, biotechnology delivered another quarter of solid growth as local companies continued to partner with Cytiva on the development of novel molecules," Rainer noted, underscoring the geographic diversification.
The Masimo acquisition closed in early June, ahead of schedule, and is off to a strong start with high single-digit revenue growth and an FDA 510(k) for an AI-enabled opioid detection solution. Management raised full-year adjusted EPS to $8.45–$8.60, with Masimo adding ~$0.07–$0.08. The company also announced the pending acquisition of StatLab, strengthening Leica's pathology workflow with a high-margin, 85% recurring-revenue business.
The capital deployment flywheel is spinning: $900 million of buybacks in Q2 and a balance sheet positioned for more M&A. Free cash flow conversion hit 124% year-to-date, underwriting the quality of earnings. As Rainer summarized, "We remain confident that growth will accelerate toward a mid-single digit exit rate this year."
“We were encouraged to see growth accelerate with improving trends across our end markets and recent innovations further driving growth across our businesses.” — 2026-07-21
The takeaway: the underlying demand story is intact, and the bioprocessing timing issue is a 2026 accounting artifact that could become a 2027 tailwind. For patient investors, the order data—not the shipped revenue—tells the real story.
“we are really encouraged to see improvement in our equipment order book with over 30% year-over-year growth.” — Rainer Blair, President and Chief Executive Officer · 2026-04-21 (April 2026 call)
“The order book fully supports the high single-digit growth that we have been talking about for 2026.” — Rainer Blair, President and Chief Executive Officer · 2026-01-28 (January 2026 call)
At current valuations—roughly 27x forward earnings with accelerating core growth—Danaher offers a rare combination of near-term conservatism and long-term optionality. The market may be pricing in a lower trajectory, but the evidence points to a company exiting 2026 with momentum and a clear runway into 2027.